4 N. Martin Luther King Jr. Blvd, Baltimore, MD 21201
Preclinical research plays a critical role in the drug development pipeline, and selecting the right models and study designs can significantly impact the success of therapeutic discovery. Biocytogen invites you to an engaging Lunch & Learn seminar where Dr. Nianbin Song will present "Biocytogen Company Overview -- Biomice Platforms: Humanized Mouse Models, Gene-Targeting & Pharmacology Capabilities".
This seminar will provide a deep dive into the importance of fully human antibodies, target-humanized mouse models, and pharmacological disease models, and their applications across drug discovery and translational research.
As a global leader in antibody drug development, gene editing, and in vivo, ex vivo, and in vitro pharmacology, Biocytogen provides a comprehensive suite ofRenSuper™ Biologics antibody platforms, BioMice™humanized and knockout models, and integrated preclinical solutions to accelerate drug discovery.
Don’t miss this opportunity to connect with fellow researchers, exchange ideas, and discover how Biocytogen’s expertise can help streamline your preclinical studies and fast-track your path to clinical success.
Why Attend?
Insightful Presentation: Learn about the services Biocytogen provides in accelerating drug development and improving research outcomes.
Engaging Discussions:Participate in discussions on the latest advancements and challenges in biotech and pharmaceuticals.
Delicious Lunch:Enjoy a carefully curated lunch box featuring local delicacies and international flavors.
RSVP Now
Spaces are limited, and this is a popular event. Secure your spot today by registering now.
About Biocytogen
Biocytogen is a global biotech company advancing antibody discovery and drug development through innovative technologies. Through its RenBiologics™ sub-brand, Biocytogen drives the discovery of fully human monoclonal, bispecific, multispecific, ADC, VHH, and TCR-mimic antibodies across 1,000+ druggable targets, providing 1M+ fully human antibody sequences for 450+ global partnerships. RenSuper Workstation™, its AI-powered antibody discovery platform, compresses early discovery timelines from years to months. Leveraging its gene-editing expertise, Biocytogen pioneered drug target knock-in humanized models and offers 5,600+ models via BioMice™, along with one-stop pharmacology and custom gene-editing services. BioMice™ has completed 10,000+ global drug evaluation projects. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).